FORA Capital LLC Takes $676,000 Position in Solventum Corporation $SOLV

FORA Capital LLC acquired a new stake in Solventum Corporation (NYSE:SOLVFree Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 8,884 shares of the company’s stock, valued at approximately $676,000.

Other large investors have also added to or reduced their stakes in the company. Concurrent Investment Advisors LLC bought a new stake in Solventum in the 1st quarter valued at $216,000. Bessemer Group Inc. raised its stake in Solventum by 17.1% in the 1st quarter. Bessemer Group Inc. now owns 1,963 shares of the company’s stock valued at $150,000 after acquiring an additional 287 shares during the period. Perigon Wealth Management LLC raised its stake in Solventum by 3.8% in the 1st quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company’s stock valued at $331,000 after acquiring an additional 159 shares during the period. Farther Finance Advisors LLC raised its stake in Solventum by 140.6% in the 1st quarter. Farther Finance Advisors LLC now owns 1,821 shares of the company’s stock valued at $139,000 after acquiring an additional 1,064 shares during the period. Finally, Amalgamated Bank raised its stake in Solventum by 1.3% in the 1st quarter. Amalgamated Bank now owns 27,120 shares of the company’s stock valued at $2,062,000 after acquiring an additional 352 shares during the period.

Solventum Stock Up 0.0%

Shares of NYSE SOLV opened at $72.94 on Thursday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. Solventum Corporation has a 52 week low of $59.35 and a 52 week high of $85.92. The stock has a market capitalization of $12.65 billion, a P/E ratio of 33.77, a PEG ratio of 1.77 and a beta of 0.52. The stock’s fifty day moving average is $73.77 and its 200 day moving average is $72.84.

Solventum (NYSE:SOLVGet Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.12 billion. During the same quarter last year, the business earned $1.56 earnings per share. Solventum’s revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SOLV has been the topic of a number of research analyst reports. Piper Sandler restated an “overweight” rating and issued a $94.00 price target (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Wells Fargo & Company increased their price target on Solventum from $75.00 to $79.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. Finally, Wall Street Zen cut Solventum from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $85.75.

Get Our Latest Stock Analysis on SOLV

About Solventum

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Read More

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.